Loading...
XASECLDI
Market cap26mUSD
Dec 23, Last price  
1.41USD
1D
3.68%
1Q
19.49%
IPO
-97.12%
Name

First Light Acquisition Group Inc

Chart & Performance

D1W1MN
XASE:CLDI chart
P/E
P/S
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
-100.00%
0449,00045,0000
Net income
-29m
L+14.90%
-7,937,0003,386,750-25,427,000-29,216,000
CFO
-27m
L+104.20%
-4,826,000-1,082,893-13,214,000-26,983,000

Profile

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.
IPO date
Sep 10, 2021
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFY
2023‑122022‑122021‑122020‑12
Income
Revenues
45
-89.98%
449
 
Cost of revenue
30,248
23,173
6,550
Unusual Expense (Income)
NOPBT
(30,248)
(23,128)
(6,101)
NOPBT Margin
Operating Taxes
16
11
11
Tax Rate
NOPAT
(30,264)
(23,139)
(6,112)
Net income
(29,216)
14.90%
(25,427)
-850.78%
3,387
-142.67%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,763
10,764
232,786
BB yield
Debt
Debt current
1,923
5,541
5,138
Long-term debt
9,682
894
222
Deferred revenue
Other long-term liabilities
2,709
15,997
Net debt
9,326
5,963
(225,707)
Cash flow
Cash from operating activities
(26,983)
(13,214)
(1,083)
CAPEX
(585)
(428)
(206)
Cash from investing activities
(478)
(494)
(230,000)
Cash from financing activities
29,044
12,087
232,146
FCF
(67,177)
18,170
(14,219)
Balance
Cash
2,049
472
1,063
Long term investments
230
230,005
Excess cash
2,279
470
231,045
Stockholders' equity
(99,615)
(60,767)
224,318
Invested Capital
101,325
25,916
12,178
ROIC
ROCE
66.36%
EV
Common stock shares outstanding
1,689
850
2,875
Price
Market cap
EV
EBITDA
(28,992)
(22,868)
(5,948)
EV/EBITDA
Interest
1,069
158
614
Interest/NOPBT